Simplifying Global Compliance
FDAnews Drug Daily Bulletin
AKORN SIGNS LETTER OF INTENT WITH AZAD PHARMA AG TO DEVELOP AND SUPPLY THREE ANDA INJECTABLE DRUG PRODUCTS
Dec. 16, 2005
Akorn, Inc. today announced that it has signed a Letter of Intent with Azad
Pharma AG, located in Toffen Switzerland, to develop and supply three ANDA injectable
drug products for critical care medicine. The Letter of Intent anticipates executing
a Definitive Agreement within ninety days upon Terms and Conditions agreeable
to both Akorn and Azad.
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing